Sessions

THE ROLE OF NEW & ENABLING TECHNOLOGIES TO DRIVE EUROPEAN CGT COMMERCIALISATION SUCCESS
STRUCTURING YOUR LOCATION & FACILITY DESIGN TO ENSURE COMMERCIAL SUCCESS
MARKET ACCESS & REIMBURSEMENT: REAL WORLD EVIDENCE & VALUE DEFINITION
INVESTING IN INVESTMENT: THE LONG TERM STRATEGY FOR CGT GROWTH IN EUROPE

THE ROLE OF NEW & ENABLING TECHNOLOGIES TO DRIVE EUROPEAN CGT COMMERCIALISATION SUCCESS

31 Aug 2022
15:30
SPONSORED BY
Emerson Automation Solutions
FUJIFILM Diosynth Biotechnologies

15:30 – CHAIR INTRODUCTION

Chair: Sven Kili, CEO, Antion Biosciences

 

15:35 – CASE STUDY: NOVEL SYNBIO APPROACHES FOR A RELIABLE & CONSISTENT SUPPLY OF HUMAN CELLS TO PRECISELY MATCH THE NEEDS OF THE PATIENT & THE DISEASE

Speaker: Mark Kotter, CEO, Bit.Bio 

 

15:50 – CASE STUDY: MOVING BEYOND GENE EDITING FOR EFFICIENT MULTIPLEX CELL ENGINEERING 

Speaker: Sven Kili, CEO, Antion Biosciences 

 

16:05 – CASE STUDY

Speaker: Daniel Marroyen, Senior Lifesciences Industry Consultant, Emerson Automation Solutions 

 

16:20 – SHOWCASE

Speaker: Joanna Norman, Senior Staff Scientist VGT, FUJIFILM Diosynth Biotechnologies

 

16:35 – Q&A SESSION WITH SPEAKERS

Speakers:

Mark Kotter, CEO, Bit.Bio

Daniel Marroyen, Senior Lifesciences Industry Consultant, Emerson Automation Solutions

Joanna Norman, Senior Staff Scientist VGT, FUJIFILM Diosynth Biotechnologies

Speakers

Sven Kili
Chief Executive Officer
Antion
Mark Kotter
Founder
Bit Bio
Daniel Marroyen
Senior Life Science Industry Consultant, Europe
Emerson Automation Solutions